Jane E. Churpek, MD, describes the BROCA genetic assay, uses targeted genomic capture and next-generation sequencing to analyze a panel of 42 genes.
Jane E. Churpek, MD, medical oncologist, hematologist, The University of Chicago, describes the BROCA genetic assay.
The BROCA assay uses new tools called targeted genomic capture and next-generation sequencing to analyze a panel of 42 genes. Of those 42 genes, 18 are breast cancer susceptibility genes, including BRCA 1 and BRCA 2.
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen